/NVAX
NVAX Stock - Novavax, Inc.
Healthcare|BiotechnologyNASDAQ
$6.66-0.30%
$0.02 (-0.30%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.28
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+117.7%upside
Target: $14.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.59 – $6.73
TARGET (TP)$14.50
STOP LOSS$6.13
RISK/REWARD1:14.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.31
52W High$11.55
52W Low$5.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $682.16M | $556.38M | $1.60B | $197.58M | $22.39M |
| Gross Profit | $479.42M | $212.61M | $696.31M | $197.58M | $22.39M |
| Gross Margin | 70.3% | 38.2% | 43.5% | 100.0% | 100.0% |
| Operating Income | $-248,931,000 | $-566,511,000 | $-644,736,000 | $-1,686,576,000 | $-416,719,000 |
| Net Income | $-187,499,000 | $-545,062,000 | $-657,939,000 | $-1,743,751,000 | $-418,259,000 |
| Net Margin | -27.5% | -98.0% | -41.1% | -882.5% | -1868.2% |
| EPS | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.43 |
Company Overview
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
42%
Hold / Neutral
4
33%
Sell / Underperform
3
25%
Analyst Consensus🔴 Bearish
5 Bullish7 Neutral/Bearish
Price Targets
$23
Average Target
↑ 247.5% Upside
Now
$6
Low
$23
Average
$110
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 24th 2025 | Cantor Fitzgerald | Resumed | Overweight | $18 |
| August 28th 2025 | H.C. Wainwright | Resumed | Buy | $10 |
| August 20th 2025 | BofA Securities | Downgrade | Underperform | $7 |
| June 17th 2025 | Citigroup | Initiation | Sell | $6 |
| February 28th 2025 | BTIG Research | Initiation | Buy | $19 |
| July 30th 2024 | JP Morgan | Downgrade | Underweight | $8 |
| May 10th 2024 | BofA Securities | Upgrade | Neutral | $12← $4 |
| May 10th 2024 | JP Morgan | Upgrade | Neutral | - |
| August 9th 2023 | B. Riley Securities | Upgrade | Buy | $15 |
| April 20th 2023 | TD Cowen | Downgrade | Market Perform | $10← $55 |
| March 1st 2023 | B. Riley Securities | Downgrade | Neutral | $10← $29 |
| January 9th 2023 | B. Riley Securities | Reiterated | Buy | $37← $74 |
| December 30th 2022 | H.C. Wainwright | Reiterated | Buy | $110← $207 |
| December 2nd 2022 | Jefferies | Initiation | Hold | - |
| September 22nd 2022 | JP Morgan | Downgrade | Underweight | $27← $132 |
Earnings History & Surprises
NVAXBeat Rate
39%
Last 18 quarters
Avg Surprise
+2.2%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-0.62
Q4 2025
EPS Surprise History
Q1 24
-193.9%
$-1.44vs$-0.49
Q2 24
-1.0%
$-1.05vs$-1.04
Q3 24
-39.6%
$0.99vs$1.64
Q4 24
+12.6%
$-0.76vs$-0.87
Q1 25
+32.0%
$-0.51vs$-0.75
Q2 25
+312.7%
$2.93vs$0.71
Q3 25
+985.7%
$0.62vs$-0.07
Q4 25
+42.6%
$-0.62vs$-1.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.66 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.08 | $-0.62 | +42.6% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.07 | $0.62 | +985.7% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $0.71 | $2.93 | +312.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.75 | $-0.51 | +32.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.87 | $-0.76 | +12.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $1.64 | $0.99 | -39.6% | ✗ MISS |
Q2 2024 | May 10, 2024 | $-1.04 | $-1.05 | -1.0% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.49 | $-1.44 | -193.9% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-1.82 | $-1.26 | +30.8% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.39 | $0.58 | +141.7% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-3.38 | $-3.41 | -0.9% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.92 | $-2.28 | -147.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $2.21 | $-2.15 | -197.3% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $5.51 | $-6.53 | -218.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $2.69 | $2.56 | -4.8% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-1.43 | $-11.18 | -681.8% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-4.04 | $-4.31 | -6.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-3.76 | $-4.75 | -26.3% | ✗ MISS |
Latest News
'FDA Chief Says No Plans To Put Boxed Warning On Covid Vaccines' - Bloomberg News
📈 PositiveBenzinga•Dec 15, 2025, 09:49 PM•Also: , ,
Reuters Issues Correction: U.S. FDA Says "Doing A Thorough Investigation, Across Multiple Age Groups, Of Deaths Potentially Related To Covid Vaccines"
📉 NegativeBenzinga•Dec 9, 2025, 08:54 PM•Also: , ,
Bloomberg: FDA Probes If Covid Shots Might Be Linked to Deaths of Adults
📉 NegativeBenzinga•Dec 9, 2025, 07:13 PM•Also: , ,
Shares of vaccine stocks are trading lower after reports indicating Center for Biologics Evaluation and Research Director Vinay Prasad plans to tighten how vaccines win federal approval, claiming links to child deaths.
📉 NegativeBenzinga•Dec 1, 2025, 04:14 PM•Also: , ,
Novamax rises after a seven-day slide
📈 PositiveSeeking Alpha•Nov 21, 2025, 06:03 PM
Novavax rises after a seven-day slide
📈 PositiveSeeking Alpha•Nov 21, 2025, 06:03 PM
B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16
➖ NeutralBenzinga•Nov 10, 2025, 03:27 PM
UPDATE: Novavax Q3 Adj. EPS $(0.48) Beats $(1.19) Estimate, Sales $70.445M Beat $42.133M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 02:27 PM
Novavax Raises FY2025 Sales Guidance from $1.000B-$1.050B to $1.040B-$1.060B vs $1.051B Est
📈 PositiveBenzinga•Nov 6, 2025, 01:03 PM
Novavax Q3 EPS $(1.25) Beats $(1.33) Estimate, Sales $70.445M Beat $42.133M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:54 PM
TD Cowen Maintains Hold on Novavax, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 4, 2025, 06:38 PM
Novavax To Transfer Marketing Authorization Of Nuvaxovid To Sanofi Under FDA Approval; Sanofi To Pay $25M Milestone Payment
📈 PositiveBenzinga•Nov 4, 2025, 11:16 AM•Also:
'US Fires Top Health Official Who Opposed Widely Used Covid Shots' -Bloomberg
📉 NegativeBenzinga•Oct 28, 2025, 12:50 PM•Also: , ,
Cantor Fitzgerald Initiates Coverage On Novavax with Overweight Rating, Announces Price Target of $18
📈 PositiveBenzinga•Oct 24, 2025, 01:24 PM•Also:
HC Wainwright & Co. Maintains Buy on Novavax, Raises Price Target to $11
📈 PositiveBenzinga•Oct 23, 2025, 01:57 PM
Novavax Executes Maryland Site Consolidation, Securing $60 Million In Cash And $230 Million In Future Savings
📈 PositiveBenzinga•Oct 22, 2025, 11:16 AM
Novavax shares are trading higher after Shah Capital urged the company's board to pursue a strategic review and potential sale.
📈 PositiveBenzinga•Oct 14, 2025, 02:22 PM
Shah Capital Urges Novavax Board To Pursue Strategic Review And Potential Sale Amid Persistent Underperformance And Market Share Losses
📉 NegativeBenzinga•Oct 14, 2025, 02:05 PM
Novavax Completes EU Marketing Authorization Transfer of COVID-19 Vaccine to Sanofi, Secures $25M Milestone Payment
📈 PositiveBenzinga•Oct 7, 2025, 11:08 AM•Also:
Novavax Achieves Key Milestone With Sanofi, Completing Nuvaxovid EU Marketing Authorization Transfer And Securing $25M Payment
📈 PositiveBenzinga•Oct 7, 2025, 11:08 AM•Also:
Frequently Asked Questions about NVAX
What is NVAX's current stock price?
Novavax, Inc. (NVAX) is currently trading at $6.66 per share. The stock has moved -0.30% today.
What is the analyst price target for NVAX?
The average analyst price target for NVAX is $14.50, based on 1 analyst.
What sector is Novavax, Inc. in?
Novavax, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NVAX's market cap?
Novavax, Inc. has a market capitalization of $1.08 billion, making it a small-cap company.
Does NVAX pay dividends?
No, Novavax, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCVAC
CureVac N.V.
$4.16
Mkt Cap: $0.9B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
ORIC
ORIC Pharmaceuticals, Inc.
$8.04
Mkt Cap: $0.8B
PGEN
Precigen, Inc.
$4.32
Mkt Cap: $1.3B
TERN
Terns Pharmaceuticals, Inc.
$39.90
Mkt Cap: $3.6B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZBIO
Zenas BioPharma, Inc.
$36.15
Mkt Cap: $1.5B
Explore stocks similar to NVAX for comparison